Shots: Italian pharmaceutical company, Leadiant Biosciences have gradually increased price of CDCA (chenodeoxycholic acid) from €300 year to more than €150,000, with EU’s approval in 2017 for the treatment of CTX (cerebrotendinous xanthomatosis) Doctors treating CTX patients at Amsterdam Medical Center are now developing a low-priced drug against Leadiant’s CDCA. Dutch health insurers have extended […]Read More
